NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Price Down 7.3%

Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBOGet Rating) dropped 7.3% during mid-day trading on Friday . The stock traded as low as $0.26 and last traded at $0.28. Approximately 92,621 shares changed hands during trading, a decline of 69% from the average daily volume of 301,500 shares. The stock had previously closed at $0.30.

NeuroBo Pharmaceuticals Stock Down 7.3 %

The firm has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.58. The firm has a market cap of $7.36 million, a price-to-earnings ratio of -0.49 and a beta of 0.49.

NeuroBo Pharmaceuticals (NASDAQ:NRBOGet Rating) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. Equities research analysts anticipate that NeuroBo Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroBo Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBOGet Rating) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 59,356 shares of the company’s stock, valued at approximately $28,000. Renaissance Technologies LLC owned about 0.22% of NeuroBo Pharmaceuticals at the end of the most recent quarter. 27.53% of the stock is owned by institutional investors and hedge funds.

NeuroBo Pharmaceuticals Company Profile

(Get Rating)

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19.

See Also

Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.